Organization
The Third Hospital of Shandong Province
1 abstract
Abstract
Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).Org: Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, The Third Hospital of Shandong Province, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Yantai Yuhuangding Hospital,